IL-22 induces lipopolysaccharide-binding protein in hepatocytes: A potential systemic role of IL-22 in Crohn's disease

Journal of Immunology

Volumn 178, Issue 9, 2007, Pages 5973-5981

  Wolk, Kerstin ^a   Witte, Ellen ^a   Hoffmann, Ute ^a   Doecke, Wolf Dietrich ^b   Endesfelder, Stefanie ^a   Asadullah, Khusru ^b   Sterry, Wolfram ^a   Volk, Hans Dieter ^a   Wittig, Bianca Maria ^a   Sabat, Robert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN RECEPTOR; LIPOPOLYSACCHARIDE BINDING PROTEIN; MEMBRANE RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BINDING AFFINITY; BLOOD LEVEL; CELL INFILTRATION; COLITIS; COLON; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LIVER CELL; LYMPH NODE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; TH1 CELL; TH17 CELL;

EID: 34247556456     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.9.5973     Document Type: Article

References (50)

1. Dumoutier, L., J. Louahed, and J. C. Renauld. 2000. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TTF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J. Immunol. 164: 1814-1819.
2. Wolk, K., and R. Sabat. 2006. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 17: 367-380.
3. Wolk, K., S. Kunz, K. Asadullah, and R. Sabat. 2002. Cutting edge: immune cells as sources and targets of the IL-10 family members? J. Immunol. 168: 5397-5402.
4. Wolk, K., E. Witte, E. Wallace, W. D. Docke, S. Kunz, K. Asadullah, H. D. Volk, W. Sterry, and R. Sabat. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 36: 1309-1323.
5. + T lymphocytes. Cell Res. 16: 902-907.
6. Liang, S. C., X. Y. Tan, D. P. Luxenberg, R. Karim, K. Dunussi-Joannopoulos, M. Collins, and L. A. Fouser. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203: 2271-2279.
7. Zheng, Y., D. M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, and W. Ouyang. 2006. Interleukin-22, a Th17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648-651.
8. King, C., and N. Sarvetnick. 1997. Organ-specific autoimmunity. Curr. Opin. Immunol. 9: 863-871.
9. Singh, V. K., S. Mehrotra, and S. S. Agarwal. 1999. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol. Res. 20: 147-161.
10. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
11. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
12. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
13. Yen, D., J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. McKenzie, M. A. Kleinschek, A. Owyang, J. Mattson, W. Blumenschein, et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116: 1310-1316.
14. Wolk, K., E. Witte, U. Reineke, K. Witte, M. Friedrich, W. Sterry, K. Asadullah, H. D. Volk, and R. Sabat. 2005. Is there an interaction between interleukin-10 and interleukin-22? Genes Immun. 6: 8-18.
15. Dumoutier, L., D. Lejeune, D. Colau, and J. C. Renauld. 2001. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J. Immunol. 166: 7090-7095.
16. Kotenko, S. V., L. S. Izotova, O. V. Mirochnitchenko, E. Esterova, H. Dickensheets, R. P. Donnelly, and S. Pestka. 2001. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J. Immunol. 166: 7096-7103.
17. Xu, W., S. R. Presnell, J. Parrish-Novak, W. Kindsvogel, S. Jaspers, Z. Chen, S. R. Dillon, Z. Gao, T. Gilbert, K. Madden, et al. 2001. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc. Natl. Acad. Sci. USA 98: 9511-9516.
18. Gruenberg, B. H., A. Schoenemeyer, B. Weiss, L. Toschi, S. Kunz, K. Wolk, K. Asadullah, and R. Sabat. 2001. A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta. Genes Immun. 2: 329-334.
19. 2 and comparison with its human counterpart. Genes Immun. 5: 330-336.
20. Wolk, K., S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat. 2004. IL-22 increases the innate immunity of tissues. Immunity 21: 241-254.
21. Dumoutier, L., E. Van Roost, D. Colau, and J. C. Renauld. 2000. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc. Natl. Acad. Sci. USA 97: 10144-10149.
22. Radaeva, S., R. Sun, H. N. Pan, F. Hong, and B. Gao. 2004. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332-1342.
23. Boniface, K., F. X. Bernard, M. Garcia, A. L. Gurney, J. C. Lecron, and F. Morel. 2005. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174: 3695-3702.
24. Farkas, S., M. Hornung, C. Sattler, M. Anthuber, U. Gunthert, H. Herfarth, H. J. Schlitt, E. K. Geissler, and B. M. Wittig. 2005. Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin. Exp. Immunol. 142: 260-267.
25. Wolk, K., S. Kunz, N. E. Crompton, H. D. Volk, and R. Sabat. 2003. Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance. J. Biol. Chem. 278: 18030-18036.
26. Obermeier, F., H. Schwarz, N. Dunger, U. G. Strauch, N. Grunwald, J. Scholmerich, and W. Falk. 2003. OX40/OX40L interaction induces the expression of CXCR5 and contributes to chronic colitis induced by dextran sulfate sodium in mice. Eur. J. Immunol. 33: 3265-3274.
27. Cobrin, G. M., and M. T. Abreu. 2005. Defects in mucosal immunity leading to Crohn's disease. Immunol. Rev. 206: 277-295.
28. Fuss, I. J., C. Becker, Z. Yang, C. Groden, R. L. Hornung, F. Heller, M. F. Neurath, W. Strober, and P. J. Mannon. 2006. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12p40 monoclonal antibody. Inflamm. Bowel Dis. 12: 9-15.
29. Andoh, A., Z. Zhang, O. Inatomi, S. Fujino, Y. Deguchi, Y. Araki, T. Tsujikawa, K. Kitoh, S. Kim-Mitsuyama, A. Takayanagi, et al. 2005. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129: 969-984.
30. Brand, S., F. Beigel, T. Olszak, K. Zitzmann, S. T. Eichhorst, J. M. Otte, H. Diepolder, A. Marquardt, W. Jagla, A. Popp, et al. 2006. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. 290: G827-G838.
31. Gaudio, E., G. Taddei, A. Vetuschi, R. Sferra, G. Frieri, G. Ricciardi, and R. Caprilli. 1999. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig. Dis. Sci. 44: 1458-1475.
32. Wei, C. C., T. W. Ho, W. G. Liang, G. Y. Chen, and M. S. Chang. 2003. Cloning and characterization of mouse IL-22 binding protein. Genes Immun. 4: 204-211.
33. Fernandez-Botran, R., and E. S. Vitetta. 1991. Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J. Exp. Med. 174: 673-681.
34. Peleg-Shulman, T., L. C. Roisman, G. Zupkovitz, and G. Schreiber. 2004. Optimizing the binding affinity of a carrier protein: a case study on the interaction between soluble ifnar2 and interferon β. J. Biol. Chem. 279: 18046-18053.
35. Logsdon, N. J., B. C. Jones, K. Josephson, J. Cook, and M. R. Walter. 2002. Comparison of interleukin-22 and interleukin-10 soluble receptor complexes. J. Interferon Cytokine Res. 22: 1099-1112.
36. Kitchens, R. L., and P. A. Thompson. 2005. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J. Endotoxin Res. 11: 225-229.
37. Lejeune, D., L. Dumoutier, S. Constantinescu, W. Kruijer, J. J. Schuringa, and J. C. Renauld. 2002. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line: pathways that are shared with and distinct from IL-10. J. Biol. Chem. 277: 33676-33682.
38. Sugimoto, K., A. Ogawa, Y. Shimomura, E. Mizoguchi, A. K. Bhan, and A. Mizoguchi. 2006. Therapeutic approach using interleukin-22 in experimental colitis. In 4th Annual Broad Medical Research Program Investigator Meeting. March 23-24. Los Angeles, CA (Abst.).
39. Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. Fujiyama. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70.
40. Schumann, R. R., S. R. Leong, G. W. Flaggs, P. W. Gray, S. D. Wright, J. C. Mathison, P. S. Tobias, and R. J. Ulevitch. 1990. Structure and function of lipopolysaccharide binding protein. Science 249: 1429-1431.
41. Myc, A., J. Buck, J. Gonin, B. Reynolds, U. Hammerling, and D. Emanuel. 1997. The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin. Diagn. Lab. Immunol. 4: 113-116.
42. Jack, R. S., X. Fan, M. Bernheiden, G. Rune, M. Ehlers, A. Weber, G. Kirsch, R. Mentel, B. Furll, M. Freudenberg, et al. 1997. Lipopolysaccharide- binding protein is required to combat a murine Gram-negative bacterial infection. Nature 389: 742-745.
43. Schroder, N. W., and R. R. Schumann. 2005. Non-LPS targets and actions of LPS binding protein (LBP). J. Endotoxin Res. 11: 237-242.
44. Lamping, N., R. Dettmer, N. W. Schroder, D. Pfeil, W. Hallatschek, R. Burger, and R. R. Schumann. 1998. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J. Clin. Invest. 101: 2065-2071.
45. Zweigner, J., H. J. Gramm, O. C. Singer, K. Wegscheider, and R. R. Schumann. 2001. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 98: 3800-3808.
46. Hamann, L., C. Stamme, A. J. Ulmer, and R. R. Schumann. 2002. Inhibition of LPS-induced activation of alveolar macrophages by high concentrations of LPS-binding protein. Biochem. Biophys. Res. Commun. 295: 553-560.
47. Grunwald, U., X. Fan, R. S. Jack, G. Workalemahu, A. Kallies, F. Stelter, and C. Schutt. 1996. Monocytes can phagocytose Gram-negative bacteria by a CD14-dependent mechanism. J. Immunol. 157: 4119-4125.
48. Klein, R. D., G. L. Su, C. Schmidt, A. Aminlari, L. Steinstraesser, W. H. Alarcon, H. Y. Zhang, and S. C. Wang. 2000. Lipopolysaccharide-binding protein accelerates and augments Escherichia coli phagocytosis by alveolar macrophages. J. Surg. Res. 94: 159-166.
49. Kirschning, C. J., A. Unbehaun, G. Fiedler, W. Hallatschek, N. Lamping, D. Pfeil, and R. R. Schumann. 1997. The transcriptional activation pattern of lipopolysaccharide binding protein (LBP) involving transcription factors AP-1 and C/EBPβ. Immunobiology 198: 124-135.
50. Schumann, R. R., C. J. Kirschning, A. Unbehaun, H. P. Aberle, H. P. Knope, N. Lamping, R. J. Ulevitch, and F. Herrmann. 1996. The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins. Mol. Cell. Biol. 16: 3490-3503.